Contrast Agent Gains Expanded Use in Liver Ultrasonography

This is the first FDA approved liver imaging agent that can ID malignant and benign focal hepatic lesions
This is the first FDA approved liver imaging agent that can ID malignant and benign focal hepatic lesions

Bracco Diagnostics announced that the Food and Drug Administration (FDA) has expanded the use of Lumason (sulfur hexafluoride lipid microsphere) for use in ultrasonography of the liver for characterization of focal liver lesions in adults and pediatric patients. 

This marks Lumason as the first ultrasound contrast agent to obtain FDA approval for use in liver imaging, to improve the sensitivity and specificity of ultrasonography for the differentiation between malignant and benign focal hepatic lesions; it is also the first ultrasound contrast agent approved for use in the pediatric population. 

RELATED: Non-Invasive Test Available for Gastroparesis Diagnosis

Lumason was initially approved in October 2014 for use in adults with suboptimal echocardiograms, to opacify the left ventricular chamber, and to improve the delineation of the left ventricular endocardial border in adults. It consists of gas-filled microspheres that reflect sound waves to enhance images in ultrasonography

Lumason is supplied as a 3-part kit that contains a vial of 25mg lipid-type A lyophilized powder and 60.7mg sulfur hexafluoride headspace.

For more information call (800) 257-581 or visit Bracco.com.

Loading links....